Pharm-Rx Methotrexate USP

Methotrexate contains NLT 98.0% and NMT 102.0% of methotrexate (C₂₀H₂₂N₈O₅), calculated on the anhydrous basis.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

• USP R-Methotrexate RS
• (R)-2-(4-{[(2,4-Diaminopteridin-6-yl)methyl](methyl) amino}benzamido)pentanedioic acid.
• C₂₀H₂₂N₈O₅ 454.45
• Sodium (R)-2-(4-{[(2,4-Diaminopteridin-6-yl)methyl] (methyl)amino}benzamido)pentanedioate.
• C₂₀H₂₀N₈Na₂O₅ 498.41
• USP Methotrexate System Suitability Mixture RS

This mixture contains:

• Methotrexate Methotrexate dimethylester hydrochloride; (S)-Dimethyl-2-(4-{[(2,4-diaminopteridin-6-yl)methyl] (methyl)amino}benzamido) pentanedioate hydrochloride. C₂₂H₂₆N₈O₅
• Methotrexate related compound I; (S)-4-(4-{[(2,4-Diaminopteridin-6-yl)methyl](methyl) amino}benzamido)-5-methoxy-5-oxopentanoic acid. C₂₁H₂₄N₈O₅ 468.47
• USP Methotrexate RS USP Methotrexate Related Compound B RS (S)-2-{4-[(2,4-Diaminopteridin-6-yl)methylamino] benzamido}pentanedioic acid. C₁₉H₂₀N₈O₅ 440.42 USP
• Methotrexate Related Compound C RS (S)-2-(4-{[(2-Amino-4-oxo-1,4-dihydropteridin-6-yl) methyl](methyl)amino}benzamido)pentanedioic acid. C₂₀H₂₁N₇O₆ 455.42
• USP Methotrexate Related Compound E RS 4-{[(2,4-Diaminopteridin-6-yl)methyl](methyl)amino} benzoic acid, hemihydrochloride. C₁₅H₁₅N₇O₂ · 1⁄2HCl 343.56